As on Wednesday, Black Diamond Therapeutics Inc (NASDAQ: BDTX) got off with the flyer as it spiked 5.95% to $5.70, before settling in for the price of $5.38 at the close. Taking a more long-term approach, BDTX posted a 52-week range of $1.43-$6.85.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 0.00%. Meanwhile, its Annual Earning per share during the time was -49.79%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 8.95%. This publicly-traded company’s shares outstanding now amounts to $51.65 million, simultaneously with a float of $38.11 million. The organization now has a market capitalization sitting at $294.80 million. At the time of writing, stock’s 50-day Moving Average stood at $4.79, while the 200-day Moving Average is $3.47.
Black Diamond Therapeutics Inc (BDTX) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Black Diamond Therapeutics Inc’s current insider ownership accounts for 26.30%, in contrast to 68.13% institutional ownership. According to the most recent insider trade that took place on Oct 17 ’23, this organization’s 10% Owner bought 400,000 shares at the rate of 2.34, making the entire transaction reach 934,080 in total value, affecting insider ownership by 8,517,839. Preceding that transaction, on Jul 05 ’23, Company’s Director bought 1,000,000 for 5.00, making the whole transaction’s value amount to 5,000,000. This particular insider is now the holder of 4,448,757 in total.
Black Diamond Therapeutics Inc (BDTX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 15.00 per share during the current fiscal year.
Black Diamond Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 8.95% and is forecasted to reach -1.79 in the upcoming year.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Trading Performance Indicators
Let’s observe the current performance indicators for Black Diamond Therapeutics Inc (BDTX). It’s Quick Ratio in the last reported quarter now stands at 6.82. The Stock has managed to achieve an average true range (ATR) of 0.44.
In the same vein, BDTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.92, a figure that is expected to reach -0.43 in the next quarter, and analysts are predicting that it will be -1.79 at the market close of one year from today.
Technical Analysis of Black Diamond Therapeutics Inc (BDTX)
Through scrutinizing the latest numbers posted by the [Black Diamond Therapeutics Inc, BDTX], it can be observed that its last 5-days Average volume of 0.53 million was lower the volume of 0.57 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 63.21% While, its Average True Range was 0.45.
Raw Stochastic average of Black Diamond Therapeutics Inc (BDTX) in the period of the previous 100 days is set at 87.42%, which indicates a major rise in contrast to 69.09% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 78.77% that was lower than 90.89% volatility it exhibited in the past 100-days period.
